Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...
Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...
TG Therapeutics reported early Phase 1 data for azer-cel in progressive multiple sclerosis and presented extensive long term ...
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
Mexico's health regulator authorized the country's first clinical trial using domestically manufactured CAR-T cells, allowing ...
The case study demonstrates a durable complete response in a heavily pretreated DLBCL patient after a single administration ...
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for ...
A Hong Kong phase II trial of six children found that locally manufactured point-of-care CD19 CAR-T cells, produced in 14 ...
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial; Updated deep B cell depletion and clinical response data is consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results